Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Rei Kudo(National Cancer Centre Japan), Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center)
Cited by 8
Related Papers
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
|Oncogene|2016|430
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer
|Nature Genetics|2015|166
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function
|Oncogene|2018|149
HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
|Nature Communications|2021|86